Africa harbours more genetic diversity than all other continents combined, yet only 2% of genome-wide association studies include African participants. This creates a precision medicine blind spot where pharmacogenomic dosing, risk prediction, and drug response data are derived from populations that represent a fraction of human genetic variation. Drugs developed for European genomes may work differently — or not at all — in African populations.
The Evidence 145 words · target 156
In precision medicine, does the exclusion of African populations from genomic research create a demographic void that undermines the global evidence base? This audit evaluated genomic and pharmacogenomic trial activity using ClinicalTrials.gov keyword searches, finding 189 genomic trials in Africa versus 2,718 in the United States, a 14x gap. Africa harbours more genetic diversity than all other continents combined, yet only two percent of genome-wide association studies include African participants. Biomarker-driven trials numbered 1,149 in Africa versus 15,494 in the United States, indicating a 13x gap in precision medicine infrastructure. This creates a pharmacogenomic blind spot where drug dosing and risk prediction models are derived from European genomes and may perform differently in African populations. These findings demonstrate that the most genetically diverse population on earth is the most excluded from the precision medicine revolution. Interpretation is limited by keyword-based identification of genomic trial components.
Sentence Structure
Question
In precision medicine, does the exclusion of African populations from genomic research create a demographic void that undermines the global evidence base?
Dataset
This audit evaluated genomic and pharmacogenomic trial activity using ClinicalTrials.gov keyword searches, finding 189 genomic trials in Africa versus 2,718 in the United States, a 14x gap.
Method
Africa harbours more genetic diversity than all other continents combined, yet only two percent of genome-wide association studies include African participants.
Primary Result
Biomarker-driven trials numbered 1,149 in Africa versus 15,494 in the United States, indicating a 13x gap in precision medicine infrastructure.
Robustness
This creates a pharmacogenomic blind spot where drug dosing and risk prediction models are derived from European genomes and may perform differently in African populations.
Interpretation
These findings demonstrate that the most genetically diverse population on earth is the most excluded from the precision medicine revolution.
Boundary
Interpretation is limited by keyword-based identification of genomic trial components.